Abstract:Hyperlipidaemia is a pivotal risk factor for the development of atherosclerotic disease. A large number of studies have demonstrated that the treatment of abnormalities in lipoprotein levels reduces the risk for myocardial infarction, peripheral vascular disease, carotid artery disease, stroke, and cardiovascular mortality. Despite the development of multiple drug classes to treat dyslipidaemias and the promulgation of clearly defined guidelines for the management of lipid disorders, dyslipidaemia tends to be undertreated in the majority of patients at risk for cardiovascular disease. A part of the reluctance to treat different lipoprotein fractions to goal levels is attributable to physician- and patient-related concerns over the increasing toxicity of available therapies, as their dosages are increased. The risks of hepatotoxicity, myalgia, and rhabdomyolysis are fairly well characterised in patients receiving statins, fibrates and niacin. Another issue affecting treatment success rates is the fact that many patients with complex dyslipidaemias are inadequately responsive to single-agent therapy. As the epidemics of obesity, metabolic syndrome and diabetes mellitus continue to worsen, physicians will encounter severe, mixed dyslipidaemias more frequently. Many of these patients will require combinations of drugs to address the various metabolic derangements causing changes in multiple lipoprotein fractions. Although the need for combination therapy is well-established in the management of disorders, such as hypertension and diabetes, it is less often used for the treatment of dyslipidaemias. The development of safe, cost-effective, and efficacious combination dyslipidaemic therapy is an important goal in cardiovascular medicine. Simvastatin plus ezetimibe has recently been combined as a fixed dose therapy, which offers clinicians the opportunity to simultaneously inhibit two key pathways in cholesterol metabolism: hepatic cholesterol biosynthesis and the absorption of cholesterol at the level of the proximal jejunum. This dual mechanism of inhibition substantially increases the capacity to decrease serum levels of atherogenic low-density lipoproteins and increase high-density lipoprotein, compared with that observed when either drug is used alone. This combination increases the likelihood of therapeutic success in patients with dyslipidaemia.

Combination of Lipid-Lowering Drugs and the Safety Monitoring

Efficacy of Statin Monotherapy or in Combination with Coenzyme A Capsule in Patients with Metabolic Syndrome and Mixed Dyslipidemia

Effect and Safety of Combination Lipid‐lowering Therapies Based on Statin Treatment Versus Statin Monotherapies on Patients with High Risk of Cardiovascular Events

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Statins and Prevention of Stroke in Patients with Non-Alcoholic Fatty Liver Disease

Efficacy and Tolerability of Adding Coenzyme A 400 U/d Capsule to Stable Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia: an 8-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study

[The Lipid-Regulating Effect and Safety of Combined Statin and Bezafibrate Therapy in Acute Coronary Syndrome Patients Complicating with Dyslipidemia].

Optimization of combined lipid-lowering therapy:reassessment of the intervention of residual cardiovascular risk in diabetic patients

[Efficacy and Safety of Combination Therapy with Simvastatin and Fenofibrate for Combined Hyperlipidemia].

VARIABILITY IN PLASMA LIPIDS BETWEEN INTENSIVE STATINS THERAPY AND CONVENTIONAL DOSE STATINS COMBINED WITH EZETIMIBE THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS DISEASE

The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial

The Influence of Statin-Fibrate Combination Therapy on Lipids Profile and Apolipoprotein A5 in Patients with Acute Coronary Syndrome

Update on the efficacy and safety of combination ezetimibe plus statin therapy

Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials.

Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data

Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia

Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia

SAFETY OF FENOFIBRATE-STATIN THERAPY VERSUS STATIN ALONE: A META-ANALYSIS

Clinical efficacy and safety of acupuncture combined with statin in dyslipidemia: A meta-analysis and system review